鼻腔疫苗市場－全球產業規模、佔有率、趨勢、機會、預測：按疫苗類型、應用、地區和競爭格局分類，2021-2031年

全球鼻內疫苗市場預計將從 2025 年的 4.3421 億美元大幅成長至 2031 年的 6.2329 億美元，複合年成長率為 6.21%。

這些疫苗是透過呼吸系統給藥的免疫誘導劑，透過誘導全身和局部黏膜免疫，有效預防病原體入侵早期階段的感染。推動該市場成長的主要因素是其非侵入性。這消除了注射針頭帶來的風險，顯著提高了病患的依從性，並減輕了醫護人員的工作量。截至2025年，美國僅有一種獲得FDA核准的鼻腔疫苗，但包括印度和俄羅斯在內的其他四個國家已獲得針對COVID-19的鼻腔製劑的緊急使用授權。

市場促進因素

此外，鼻內疫苗能夠誘導黏膜免疫和殺菌免疫，其卓越的免疫力是推動該市場成長的主要因素。這相比於全身免疫具有決定性優勢，因為全身免疫往往不足以預防病原體傳播。與主要誘發體液免疫反應的注射疫苗不同，鼻內製劑能夠直接刺激呼吸道病毒入侵部位的分泌型免疫球蛋白A（IgA）。這不僅對預防重症至關重要，而且對阻斷感染和控制社區傳播也至關重要。例如，據辛辛那提兒童醫院稱，截至2025年7月，在早期臨床試驗中，臨床實驗經鼻吸入型疫苗「CVXGA」已顯示出可將感染風險降低67%。此外，對非侵入性、無針給藥方式的需求日益成長，正在透過提高患者依從性和提升大規模免疫接種效率來改變市場格局。這尤其有利於兒童和有針頭恐懼症的人群，也允許他們自行接種。這項轉變得益於美國食品藥物管理局 (FDA)核准的鼻噴劑流感疫苗於 2026 年 1 月上市，可供患者自行接種或看護者。這種需求的激增正在推動疫苗研發，根據 PLOS 報道，截至 2025 年 5 月，全球開發平臺中將有 34 種黏膜 COVID-19 疫苗候選產品處於臨床試驗階段。

市場挑戰

儘管鼻內疫苗具有上述優勢，但全球鼻內疫苗市場仍面臨一個重要的生物屏障：黏膜纖毛清除。這種生理機制會迅速地將外來物質從鼻腔排放，嚴重限制了疫苗抗原的吸收時間。因此，要達到足夠的免疫抗原性，就需要開發高濃度製劑和先進的遞送技術，但這往往會導致產品穩定性問題，進而影響疫苗的保存期限和大規模分銷物流。這種技術複雜性也造成了法規環境的挑戰，使得證明疫苗的持續有效性在統計上變得困難。這體現在生物製藥計畫的臨床開發成功率較低，2024年僅6.7%。這嚴重限制了最終能夠商業化的經鼻吸入型疫苗候選產品的數量，進而阻礙了整體市場收入的成長。

市場趨勢

然而，市場也正在經歷變革性趨勢。其中一個重要趨勢是，生物製劑的應用範圍已從傳統的呼吸道病原體擴展到神經系統和腫瘤領域。研發人員正在利用鼻腔給藥途徑繞過血腦障壁，用於治療神經退化性疾病，並刺激黏膜細胞毒性T淋巴細胞，用於癌症治療。例如，千葉大學於2025年11月報導了一種基於奈米凝膠的鼻腔製劑，該製劑能夠誘導針對子宮頸癌的持續抗腫瘤免疫。另一個重要趨勢是轉向使用耐熱乾粉製劑，以解決液體生技藥品固有的不穩定性問題。透過將抗原轉化為固體粉末，製造商可以省去持續低溫運輸基礎設施，防止劣化，並實現向偏遠地區的配送。這種方法延長了保存期限，改善了空氣動力學特性，提高了鼻腔內給藥效率，並克服了水性噴霧劑的限制。 2025 年 10 月，美國國立衛生研究院的一項研究證實了這一點，該研究發現一種新型乾粉佐劑系統在高溫條件下維持了 10 個月的穩定性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球鼻腔疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 疫苗類型（減毒活病毒疫苗、不活化疫苗、次單位疫苗、重組疫苗、結合疫苗、其他）
  • 依應用（流感、新冠肺炎、其他疾病（霍亂、傷寒等））
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美鼻腔疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲鼻腔疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區鼻腔疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲鼻腔疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲鼻腔疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球鼻腔疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Vaxart, Inc.
• FluGen Inc.
• Altimmune, Inc.
• Sinovac Biotech Ltd.
• Sanofi Pasteur SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Ennaid Therapeutics, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Nasal Vaccines Market is projected to expand significantly, growing from USD 434.21 Million in 2025 to USD 623.29 Million by 2031, at a Compound Annual Growth Rate of 6.21%. These vaccines are immunizing agents delivered through the respiratory tract to elicit both systemic and local mucosal immunity, effectively preventing pathogen transmission at the initial entry point. A key driver for this market's growth is their non-invasive nature, which removes risks associated with needles, substantially increases patient compliance, and eases logistical demands on healthcare professionals. While the United States had only one FDA-approved nasal vaccine in 2025, nasal COVID-19 formulations had already received emergency use authorizations in four other countries, including India and Russia.

Market Driver

The market is also strongly propelled by the superior ability of nasal vaccines to induce mucosal and sterilizing immunity, a critical advantage over systemic immunization which often falls short in preventing pathogen transmission. Unlike injectable vaccines that primarily generate humoral responses, nasal formulations directly stimulate secretory Immunoglobulin A (IgA) at the respiratory viral entry point, which is crucial for blocking infection and limiting community spread, beyond merely preventing severe disease. For instance, an investigational intranasal vaccine, CVXGA, demonstrated a 67% reduction in infection risk in early-stage trials by July 2025, according to Cincinnati Children's. Furthermore, the increasing preference for non-invasive, needle-free administration is transforming the market by enhancing patient compliance and streamlining mass immunization efforts, particularly benefiting pediatric and needle-phobic populations, and enabling self-administration. This shift was validated in January 2026 when the FDA-approved nasal spray influenza vaccine became available for self- or caregiver administration. This growing demand has fueled development, with the global pipeline including 34 mucosal COVID-19 vaccine candidates in clinical trials by May 2025, as reported by PLOS.

Market Challenge

Despite these advantages, the Global Nasal Vaccines Market faces a significant biological barrier: mucociliary clearance. This physiological mechanism rapidly expels foreign substances from the nasal cavity, severely restricting the time available for vaccine antigens to be absorbed. This necessitates the development of highly concentrated doses or sophisticated delivery technologies to achieve sufficient immunogenicity, which often leads to product stability issues, complicating shelf-life and mass distribution logistics. Such technical complexity also creates a demanding regulatory environment, as demonstrating consistent potency becomes statistically challenging. This is reflected in the low clinical development success rate for biopharmaceutical programs, which stood at a mere 6.7% in 2024, severely limiting the number of successful nasal vaccine candidates reaching commercialization and consequently stifling overall market revenue growth.

Market Trends

However, the market is simultaneously seeing transformative trends. One significant trend is the diversification into neurological and oncological applications, moving beyond traditional respiratory pathogens. Developers are utilizing the intranasal route to bypass the blood-brain barrier for neurodegenerative treatments and to stimulate mucosal cytotoxic T lymphocytes for cancer therapies. An example of this is a nanogel-based intranasal formulation reported by Chiba University in November 2025, which induced durable anti-tumor immunity for cervical cancer. Another key trend is the shift towards thermostable dry powder formulations, which addresses the inherent instability of liquid biological products. By converting antigens into solid-state powders, manufacturers can eliminate the need for continuous cold-chain infrastructure, reducing spoilage and enabling distribution to remote areas. This approach also extends shelf-life and improves aerodynamic properties for efficient nasal deposition, overcoming limitations of aqueous sprays, as demonstrated by an NIH study in October 2025 where a novel dry powder adjuvant system maintained stability for 10 months under high-temperature conditions.

Key Market Players

• Vaxart, Inc.
• FluGen Inc.
• Altimmune, Inc.
• Sinovac Biotech Ltd.
• Sanofi Pasteur SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Ennaid Therapeutics, LLC

Report Scope

In this report, the Global Nasal Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nasal Vaccines Market, By Vaccine Type

• Live Attenuated Vaccines
• Inactivated Vaccines
• Subunit
• Recombinant
• Conjugate Vaccines
• Others

Nasal Vaccines Market, By Application

• Influenza
• COVID-19
• Others

Nasal Vaccines Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nasal Vaccines Market.

Available Customizations:

Global Nasal Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nasal Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines, Others)
  • 5.2.2. By Application (Influenza, COVID-19, Others (such as Cholera, Typhoid, etc.))
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Nasal Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vaccine Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nasal Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Vaccine Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Nasal Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Vaccine Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Nasal Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Vaccine Type
      • 6.3.3.2.2. By Application

7. Europe Nasal Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vaccine Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nasal Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vaccine Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Nasal Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vaccine Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Nasal Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vaccine Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Nasal Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Vaccine Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Nasal Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Vaccine Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Nasal Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Nasal Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vaccine Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Nasal Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vaccine Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Nasal Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vaccine Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Nasal Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vaccine Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Nasal Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vaccine Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Nasal Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vaccine Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Nasal Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vaccine Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Nasal Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vaccine Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Nasal Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vaccine Type
      • 9.3.3.2.2. By Application

10. South America Nasal Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vaccine Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nasal Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vaccine Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Nasal Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vaccine Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Nasal Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vaccine Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Nasal Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Vaxart, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. FluGen Inc.
• 15.3. Altimmune, Inc.
• 15.4. Sinovac Biotech Ltd.
• 15.5. Sanofi Pasteur SA
• 15.6. Pfizer Inc.
• 15.7. GlaxoSmithKline plc
• 15.8. Johnson & Johnson
• 15.9. Ennaid Therapeutics, LLC

16. Strategic Recommendations

17. About Us & Disclaimer